CA3039643A1 - Benzimidazoles and use thereof as modulators of p300 and/or cbp activity - Google Patents

Benzimidazoles and use thereof as modulators of p300 and/or cbp activity Download PDF

Info

Publication number
CA3039643A1
CA3039643A1 CA3039643A CA3039643A CA3039643A1 CA 3039643 A1 CA3039643 A1 CA 3039643A1 CA 3039643 A CA3039643 A CA 3039643A CA 3039643 A CA3039643 A CA 3039643A CA 3039643 A1 CA3039643 A1 CA 3039643A1
Authority
CA
Canada
Prior art keywords
imidazol
benzo
compound
piperidin
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3039643A
Other languages
English (en)
French (fr)
Inventor
Neil Anthony Pegg
David Michel Adrien Taddei
Jonathan Shannon
Silvia PAOLETTA
Ting QIN
Gareth HARBOTTLE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CellCentric Ltd
Original Assignee
CellCentric Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CellCentric Ltd filed Critical CellCentric Ltd
Publication of CA3039643A1 publication Critical patent/CA3039643A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
CA3039643A 2016-10-18 2017-10-18 Benzimidazoles and use thereof as modulators of p300 and/or cbp activity Pending CA3039643A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1617627.3 2016-10-18
GBGB1617627.3A GB201617627D0 (en) 2016-10-18 2016-10-18 Pharmaceutical compounds
PCT/GB2017/053153 WO2018073587A1 (en) 2016-10-18 2017-10-18 Pharmaceutical compounds

Publications (1)

Publication Number Publication Date
CA3039643A1 true CA3039643A1 (en) 2018-04-26

Family

ID=57680679

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3039643A Pending CA3039643A1 (en) 2016-10-18 2017-10-18 Benzimidazoles and use thereof as modulators of p300 and/or cbp activity

Country Status (12)

Country Link
US (1) US10647704B2 (enExample)
EP (1) EP3529240B1 (enExample)
JP (1) JP7082616B2 (enExample)
CN (1) CN110036002B (enExample)
AU (1) AU2017346454B2 (enExample)
CA (1) CA3039643A1 (enExample)
DK (1) DK3529240T3 (enExample)
ES (1) ES2824814T3 (enExample)
GB (1) GB201617627D0 (enExample)
HU (1) HUE052107T2 (enExample)
WO (1) WO2018073587A1 (enExample)
ZA (1) ZA201902335B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201617630D0 (en) * 2016-10-18 2016-11-30 Cellcentric Ltd Pharmaceutical compounds
TWI846350B (zh) 2017-09-15 2024-06-21 美商佛瑪治療公司 作為ＣＢＰ／ｐ３００抑制劑之四氫－咪唑並喹啉化合物
MX2023013508A (es) 2018-06-29 2023-12-13 Forma Therapeutics Inc Inhibicion de la proteina de union a creb (cbp).
TW202102494A (zh) 2019-03-15 2021-01-16 美商弗瑪治療公司 抑制環amp-反應元件-結合蛋白(creb)
CN112574189B (zh) * 2019-09-27 2024-05-31 海创药业股份有限公司 一种ep300/cbp抑制剂
CN112574191B (zh) * 2019-09-29 2024-01-23 南京圣和药业股份有限公司 异噁唑杂环类化合物及其应用
US11801243B2 (en) 2020-09-23 2023-10-31 Forma Therapeutics, Inc. Bromodomain inhibitors for androgen receptor-driven cancers
US11795168B2 (en) 2020-09-23 2023-10-24 Forma Therapeutics, Inc. Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP)
TW202227429A (zh) * 2020-11-06 2022-07-16 大陸商貝達藥業股份有限公司 Ｐ３００抑制劑、包含其的藥物組合物、其應用及製備其的方法
CN116670129A (zh) * 2020-12-31 2023-08-29 南京明德新药研发有限公司 苯并咪唑类化合物及其应用
CN114989158A (zh) * 2021-03-02 2022-09-02 复旦大学 组蛋白乙酰转移酶p300溴结构域抑制剂及其药用组合物及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200501960A (en) * 2002-10-02 2005-01-16 Bristol Myers Squibb Co Synergistic kits and compositions for treating cancer
JP5536336B2 (ja) * 2005-11-08 2014-07-02 チョンウェ ファーマ コーポレイション α−ヘリックス類似体および癌幹細胞の治療に関する方法
US8501957B2 (en) 2008-12-10 2013-08-06 China Medical University Benzimidazole compounds and their use as anticancer agents
WO2011085039A2 (en) * 2010-01-05 2011-07-14 The Johns Hopkins University Use of histone acetyltransferase inhibitors as novel anti-cancer therapies
EP2397471A1 (en) 2010-06-16 2011-12-21 China Medical University Benzimidazole compounds and their use
TWI527811B (zh) 2013-05-09 2016-04-01 吉李德科學股份有限公司 作爲溴結構域抑制劑的苯並咪唑衍生物
WO2015004534A2 (en) * 2013-06-21 2015-01-15 Zenith Epigenetics Corp. Novel substituted bicyclic compounds as bromodomain inhibitors
US9763922B2 (en) * 2014-11-27 2017-09-19 Genentech, Inc. Therapeutic compounds and uses thereof
WO2016097870A1 (en) 2014-12-17 2016-06-23 Zenith Epigenetics Corp. Substituted bicyclic compounds as bromodomain inhibitors
GB201506658D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
CN114605387A (zh) 2015-08-12 2022-06-10 埃皮吉纳提克斯股份有限公司 取代的苯并咪唑、它们的制备和它们作为药物的用途
GB201617630D0 (en) * 2016-10-18 2016-11-30 Cellcentric Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
US10647704B2 (en) 2020-05-12
ES2824814T3 (es) 2021-05-13
ZA201902335B (en) 2024-11-27
DK3529240T3 (da) 2020-09-07
JP2019535658A (ja) 2019-12-12
WO2018073587A1 (en) 2018-04-26
EP3529240B1 (en) 2020-08-05
US20190263788A1 (en) 2019-08-29
HUE052107T2 (hu) 2021-04-28
CN110036002B (zh) 2022-08-30
AU2017346454B2 (en) 2022-02-17
GB201617627D0 (en) 2016-11-30
JP7082616B2 (ja) 2022-06-08
AU2017346454A1 (en) 2019-05-02
NZ752356A (en) 2025-02-28
EP3529240A1 (en) 2019-08-28
CN110036002A (zh) 2019-07-19

Similar Documents

Publication Publication Date Title
EP3529240B1 (en) Pharmaceutical compounds
US11377443B2 (en) Pharmaceutical compounds
EP3286183B1 (en) Isoxazolyl substituted benzimidazoles
EP3286188B1 (en) Isoxazolyl substituted imidazopyridines
RS62919B1 (sr) Postupci pripreme novih inhibitora idh1
EP3246330A1 (en) Imidazoles as histone demethylase inhibitors
HK40005627B (en) Pharmaceutical compounds
HK40005627A (en) Pharmaceutical compounds
BR112019007834B1 (pt) Compostos farmacêuticos
HK40006202A (en) Pharmaceutical compounds
HK40006202B (en) Pharmaceutical compounds
EA041318B1 (ru) Арилимидазолилизоксазолы и их применение
EA047871B1 (ru) Соединения, связывающие цереблон, композиции на их основе и способы лечения с их применением

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220907

EEER Examination request

Effective date: 20220907

EEER Examination request

Effective date: 20220907

EEER Examination request

Effective date: 20220907

EEER Examination request

Effective date: 20220907